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MALDI-MS Imaging is a novel label-free technique that can be used to visualize the changes in
multiple mass responses following treatment. Following treatment with proinflammatory cy-
tokine interleukin-22 (IL-22), the epidermal differentiation of Labskin, a living skin equivalent
(LSE), successfully modeled psoriasis in vitro. Masson’s trichrome staining enabled visualiza-
tion and quantification of epidermal differentiation between the untreated and IL-22 treated
psoriatic LSEs. Matrix-assisted laser desorption ionization mass spectrometry imaging was
used to observe the spatial location of the psoriatic therapy drug acetretin following 48 h treat-
ments within both psoriatic and normal LSEs. After 24 h, the drug was primarily located in the
epidermal regions of both the psoriatic and nonpsoriatic LSE models whereas after 48 h it was
detectible in the dermis.
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1 Introduction
Tissue engineering has enabled the development of skin
models. These living skin equivalents (LSEs), derived from
primary human skin cells, self-assemble to form stratified lay-
ers comparable to human skin [1–8]. LSEs offer treatment for
burns patients following serious injury, avoiding the need for
meshed skin grafts and donor skin [6–9]. Additionally, LSEs
are used for toxicity screening with the ability to replace ani-
mal models for cosmetic and drug development. The use of
skin models in drug development has been reviewed recently
[10].Whilst a 3D in vitromodel would not be expected to show
a full range of histopathological responses due to the absence
of an immune system, blood supply, or innervation, LSE of-
fers an alternative to animal models which can give useful
data for studies, for example of drug absorption/penetration.
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Psoriasis is a skin condition that causes red, flaky, crusty
patches of skin covered with silvery scales or plaques that
affects 2% of people in theUnited Kingdom (NHS 2015). One
of the markers of psoriasis as an inflammatory disease is the
interruption of normal cytokine pathways affecting cellular
communication with keratinocytes. This interruption to the
interleukin-22 (IL-22) pathway is one of the primary causes
of adverse effects to these normal inflammatory pathways,
which can cause keratin atherosclerosis, or thickening and
unevening of the epidermis within patients with psoriasis,
as shown in Fig. 1 [11–15]. Acanthosis in psoriasis is visible
with the induction of psoriatic plaques on the skin surface.
It is also responsible for the hypoproliferation of cells in the
epidermis [16]. In this study, we have added IL-22 in order
to induce psoriasis in vitro by mimicking the inflammatory
response environment present [15–17].
One of the strengths of mass spectrometry imaging (MSI)
is the ability to visualize the distribution of multiple com-
poundswithin tissues simultaneously and in a label-freeman-
ner [18]. We have previously appliedMALDI-MSI to the study
of both ex vivo human skin and 3D skin models [19–23]. MSI
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Significance of the study
The work reported here represents the first reported mass
spectrometric study of a 3D skin model modified to repre-
sent a disease state.
has recently been used to examine drug absorption in LSE,
with the aim to identify the metabolism of drugs within LSE
[24]. MALDI-MSI is continuing to grow as a robust technique
for the analysis of tissues and offers great prospects for tis-
sue engineering to compare the profile of native tissues and
diseases with those of their tissue-engineered counterparts,
overall enabling greater development of the latter.
In the study reported here, we have added IL-22 to a develop-
ing LSE in order to induce psoriasis in vitro bymimicking the
inflammatory response environment present.We have exam-
ined the effects of the IL-22 treatment on both the structure of
the LSE and the barrier function by the use of MALDI-MSI.
2 Materials and methods
2.1 Psoriatic development and LSE culture
LSE skin models at day 7 air–liquid interface (ALI; Labskin,
Innovenn, York, UK) were treated with IL-22 (R&D Sys-
tems) for 14 days to induce psoriasis. Labskin maintenance
medium (Innovenn, York, UK) was supplemented with IL-
22 (10 ng/mL) and medium was refreshed daily keeping the
LSEs at ALI. The epidermal differentiation and metabolic ac-
tivity were monitored by AlamarBlue ۚ staining every 2 days.
Psoriasis drug treatments of topical acetretin (30 L of 300
g/mL in acetone/olive oil 4:1) were applied on day 21 and
the efficacy and drug penetration within the skin models was
compared over 48 h.
2.2 Fresh frozen tissue and cryosectioning
Directly following drug treatment, LSEs were removed from
the well insert and snap frozen in a bath of precooled isopen-
tane (2–5 min) in a Styrofoam box containing liquid nitrogen
and a suitable float. LSEswere stored at−80C for at least 24 h
before sectioning. LSEs were mounted onto cork rings with
dH2O at −25C and allowed to equilibrate to temperature for
30 min before being cryosectioned at 12 m and freeze-thaw
mounted onto “polycat”microscope slides (SLS, Hessle, UK).
2.3 Hematoxylin and eosin staining
LSE sections were stained using Mayers hematoxylin (VWR)
and aqueous eosin Y (VWR) solutions. Each slide was sub-
merged in hematoxylin for 8 min, washed in running tap
water for 4 min, submerged in eosin y solution for 30 s, dH20
for 1 min, and mounted with DPX (distyrene, a plasticizer,
and xylene used as a synthetic resin mounting media) follow-
ing dehydration through a series of alcohol and xylene dehy-
dration baths. Slides were imaged using an Olympus BX60
microscope fitted with UPlanFl 10x/0.30, 20x/0.50 /0.17,
40x/0/75/0.17 objectives and analyzed with QCapture-Pro
8.0 software (QImaging, Surry, BC, Canada).
2.4 Masson’s trichrome staining
LSE sections were stained using Masson’s trichrome stain-
ing kit (VWR). Slides were submerged in hematoxylin for
10 min, washed in running tap water for 4 min, stained in
Figure 1. Simplified schematic of the
changes that occur within skin in response
to treatment with IL-22. Generally in
psoriatic patients a specific stimulus will
induce a cascade of events within skin cul-
minating with the characteristic disregu-
lated epidermis or acanthosis. The IL-23
produced by macrophages within the skin
lead to immune responses of Th17 which
produces the IL-22 of interest to this study.
IL-22 in turn is responsible for the char-
acteristic changes in the epidermis visible
through the activation of pStat3 and pso-
rasin, culminating with the production of
chemokines, which leads to angiogenesis.
Figure adapted [15].
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ponceau fuchsin for 5 min, rinsed in dH2O, submerged in
phosphomolybdic acid for 3 min, and colored without rins-
ing in vert lumiere, before being rinsed in two baths of acidi-
fied water to remove excess dye. Following staining samples
were mounted with DPX following dehydration through a
serious of alcohol and xylene dehydration baths. Slides were
imaged using an Olympus BX60 microscope fitted with UP-
lanFl 10x/0.30, 20x/0.50/0.17, 40x/0.75/0.17 objectives
and analyzed with QCapture-Pro 8.0 software (QImaging).
Epidermal thickness was measured from recorded images
using ImageJ (https://imagej.nih.gov/ij/) and statistical anal-
yseswere carried out usingStatsDirect (StatsDirect, Cheshire,
UK). A Tukey analysis of variance was performed on multi-
ple measurements taken from random sections, taken from
treated and untreated LSEs.
2.5 Immunohistochemistry
Fresh frozen tissue sections were fixed in ice-cold acetone
and endogenous peroxidases quenched. Antigen retrieval
was performed in a microwave oven in 0.05 M Tris, pH
9.5. Samples were blocked in rabbit serum, then incubated
overnight at 4C with mouse anti-human Psoriasin (1:200;
Abcam, ab13680) and with preimmune mouse IgG (Abcam)
as a negative control (1:50). After washing, samples were
incubated with biotinylated rabbit anti-mouse secondary an-
tibody (1:500; Abcam) and binding detected by formation
of streptavidin–biotin complexes (Vector Laboratories, Pe-
terborough, UK) with 3,32-diaminobenzidine tetrahydrochlo-
ride solution (Sigma–Aldrich). Sections were counterstained
with Mayers Hematoxylin (Leica Microsystems), dehydrated,
cleared, and mounted in Pertex (Leica). Sections were visual-
ized and images captured on an Olympus BX60 Microscope
using QCapture Pro version 8.0 software (Media Cybernetics,
Marlow, UK).
2.6 Small-molecule MALDI-MS imaging
For small-molecule MALDI-MS imaging, sections were
coated withMALDImatrix (-cyano-4-hydroxycinnamic acid,
5 mg/mL in 70:30 methanol: 0.5% TFA) using a SunCollectۛ
(SunChrom Friedrichsdor, Germany) sprayer. Slides were
coated with four layers of CHCA matrix, spraying each layer
approximately 50 L per layer at 2 L/min. Mass spectra
and images were acquired in positive ion mode on an Ap-
plied Biosystems/MDS Sciex hybrid quadrupole TOF mass
spectrometer (Q-Star Pulsar-i) with an orthogonal MALDI
ion source (Applied Biosystems, Foster City, CA, USA) and a
high-repetition neoddymium-doped yttrium aluminium gar-
net (Nd:YAG) laser (355 nm, 1 KHz) (Applied Biosystems).
Image acquisition was performed at a spatial resolution of
100 m × 100 m in “Raster Image” mode; images were
generated using the freely available Novartis Biomap 3.7.5.5
Figure 2. Labskin stained with AlamarBlue R© at day 21 ALI. (A)
Without treatment with IL-22 there are no visible changes to the
epidermis of the LSEs. (B) LSEs treatedwith IL-22 show disregula-
tion to the epidermis (dotted line) and psoriatic plaques (arrows)
after treatment.
software (www.maldi-msi.org). Post-MS imaging sections
were also examined by histology as described in this section.
3 Results and discussion
3.1 Psoriatic development within LSEs
Following treatment with IL-22 from day 7 ALI for 2 weeks
to day 21 ALI, psoriatic plaques were visible on the LSE con-
structs as shown in Fig. 2B (arrows). Costaining with Alamar-
Blueۚ highlighted abnormalities in epidermal differentiation
within the LSE constructs visible by deregulation of the epi-
dermal layer (acanthosis) visible in Fig. 2B (dashed lines) with
IL-22 as contrasted with the smooth epidermal layer observed
in Fig. 2A. The formation of this acanthosis within the epi-
dermis of the treated LSEs creates a similar structure to that
observed with in vivo psoriasis.
Standard H&E staining of the LSEs yielded results indicat-
ing thickening of the epidermis. In Fig. 3D following treat-
ment with IL-22, it is possible to see an upper epidermal
thickness of 85 m as opposed to 32 m in Fig. 3B with-
out treatment of IL-22. Additionally, the character of the LSEs
becomes quite characteristically wavy (i.e. exhibits disregula-
tion) in Fig. 3C following treatment with IL-22 as opposed to
Fig. 3A without.
Since standard H&E staining does not quantitatively en-
able measurement of the epidermal stratification, Masson’s
trichrome staining was performed to aid visualization of ker-
atin and collagen within the layers of the epidermis allowing
better measurements to be acquired. In Fig. 4A and B, it is
C© 2016 The Authors. Proteomics Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. www.proteomics-journal.com
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Figure 3. Histology H&E staining of
Labskin at day 21 ALI. (A) Non-IL-22
treated LSE, “normal skin.” (B) En-
larged area showing the measurable
upper epidermal thickness of non-IL-
22 treated LSE to be 32 m. (C) IL-
22 treated LSE, “psoriatic skin,” char-
acterised by wavy acanthosis. (D) En-
larged area showing the measurable
upper epidermal thickness of IL-22
treated LSE to be 85 m.
clear that there is very little stratification of the epidermis and
its structure is fairly flat, however in Fig. 4C andD, the “wavy”
psoriatic characteristic is clearly observable. The measured
total epidermal thickness (comparing Fig. 4B and D) has in-
creased from approximately 132± 14.6 m to 179± 13.6 m
(p = 0.01), i.e. the thickening is statistically significant. The
measured epidermal stratification of non-IL-22 treated Lab-
skin is 41± 5.9mand for the treated samples 78± 21.6m
(p = 0.0568), i.e. the difference is not statistically different.
In order to validate the psoriatic-like nature of the IL-22
treated LSE, immunohistochemical staining for the presence
of psoriasin was carried out. As can be seen in Fig. 5, pso-
riasin is detectable in low abundance in untreated Labskin
(Fig. 5A) but is much more highly expressed in the IL-22
treated samples (Fig. 5C). There is little indication of non-
specific binding as shown by the specific isotype controls
(Fig. 5B and D). Figure 5C also shows the epidermal thicken-
ing observed in both the H&E andMasson’s stained samples.
3.2 Drug treatment of LSEs and analysis with
MALDI-MSI
Acetretin, a psoriatic drug was chosen for its known effect to-
ward psoriatic skin [25] and also for the ability of the drug to be
visualized byMSI. The phosphatidylcholine head group (m/z
184) was chosen to enable visualization of the LSE structure
as phospholipids are abundant in tissues such as skin. The
positive phospholipid head group is key to their ionization
efficiency. Figure 6A–F show representative LSE samples,
Fig. 5A control without drug, Fig. 6B drug treated without
IL-22 (24 h posttreatment), Fig. 6C IL-22 treated, drug-treated
psoriatic LSE (24 h posttreatment) with Fig. 6E–F showing
enlarged areas of these samples. In the enlarged images fo-
cusing on the epidermis of the LSEs, drug was not observed
within the untreated control, Fig. 6D, as expected. The “red”
drug signal is, however, clearly observable in the representa-
tive images of treated samples (Fig. 6E and F). The red ace-
tretin signal (m/z 326.2) appears to be solely located within
the epidermis, by comparison with the H&E image. From
these images the depth of penetration of the drug into the
LSE can be evaluated. For the non-IL-22 treated Labskin (Fig.
6E) the apparent depth of penetration is 114 m and for
the IL-22 treated Labskin (Fig. 6F) the apparent penetration
is 177 m, an increase of approximately 63 m. This is in
agreement with the previously measured (Fig. 4) epidermal
stratification. Therefore at the 24 h time point, the distance
penetrated appears to correspond to the thickness of the epi-
dermis.
A 48 h posttreatment sample was imaged to examine drug
distribution following longer treatment (Fig. 7). In this case
a sodiated sphingomyelin (SM 34:1 [M+Na]+) at m/z 725.4
was chosen to visualize the epidermis. In Fig. 7A, the epider-
mal regions of the various LSEs can be clearly seen. In this
case, images were taken of LSEs with and without acetretin
drug treatment and both with and without IL-22 treatment.
In these preliminary results it is not possible to see a signif-
icant difference in the thickness of the epidermis using MSI
of sphinogomyelins at the 100 m spatial resolution used.
Figure 7B shows a closer look at the LSE treated with both
IL-22 and acetretin. Figure 7B shows the distribution of the
m/z 326.2 acetretin drug signal within the LSE. It is possible
to see that after 48 h the drug has been effectively delivered
C© 2016 The Authors. Proteomics Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. www.proteomics-journal.com
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Figure 4. Histology Masson’s Trich-
rome staining of Labskin at day 21
ALI. (A) Non-IL-22 treated LSE, “nor-
mal skin.” (B) Enlarged area show-
ing the measurable stratum corneum
thickness of non-IL-22 treated LSE as
20 m and stratification of the epi-
dermal region of 19 m. (C) IL-22
treated LSE, “psoriatic skin,” charac-
terised by wavy acanthosis. (D) En-
larged area showing the measurable
stratum corneum thickness of IL-22
treated LSE as 26 m and stratification
of the epidermal region of 55 m. (E)
Statisical analysis of epidermal thick-
ening observed in IL-22 treated and un-
treated Labskin (p = 0.01).
through the epidermis of the LSE into the dermal region with
now an apparent depth of penetration of approximately 557
m, the full thickness of the LSE.
Tissue engineering, and specifically skin tissue engineer-
ing has far from reached its limits. While much work was
undertaken in the 1980–2000s to develop 3D culture of cells,
and specifically tissue-engineered skin only recently have dis-
eased models of skin been developed. Psoriasis has been
linked very clearly with IL-22 pathway and as such IL-22-
transformed psoriatic LSEs are effective ways to model the
disease [15,26]. IL-22 is responsible for activation of psorasin
and pStat3 within the epidermis; these markers are visible by
C© 2016 The Authors. Proteomics Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. www.proteomics-journal.com
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Figure 5. (A–D) Immunohistochem-
istry showing Psoriasin expression
and localization in LabSkin. DAB
staining (brown) shows Psoriasin
is localized to the epidermal lay-
ers of the LSE model (A and C).
LabSkin treated with IL-22 has a thick-
ened epidermis and increased expres-
sion of Psoriasin (C).
immunohistochemistry and may be visible by MALDI-MSI.
As with many diseases much of the specific mechanisms of
psoriasis are still greatly unknown, and observing the pres-
ence of lipids, cytokines, chemokines, proteins, and peptide
markers associated with the disease would greatly impact our
understanding of the disease. This is therefore an ideal area
for further study using MSI.
4 Concluding remarks
In this studywe have been able to produce in vitro LSEmodels
of psoriasis using Labskin commercial LSE, as confirmed
by histology and have used MSI to determine the special
location of the psoriatic drug acetretin. It was possible to
demonstrate that 24hposttreatment, the acetretinwas located
Figure 6. MALDI-MSI data overlay of m/z 326.2 acetretin (red) on m/z 184 phosphatidylcholine lipid (green) of LSEs 24 h posttreatment.
(A) Non-IL-22 and nondrug-treated control. (B) Non-IL-22 and acetretin drug treated. (C) IL-22 and acetretin treated. Location of the drug is
visible in the epidermis of treated samples. (D–F) Enlarged areas enable measurement of apparent depth of penetration of acetretin in the
epidermal regions. (D) No drug signal present in the control. (E) The apparent depth of penetration within the non-IL-22 treated LSE is 114
m. (F) The apparent depth of penetration within the IL-22 treated psoriatic LSE is 177 m. The apparent larger abundance of drug within
the psoriatic (+IL-22) LSE at 24 h posttreatment is explainable by the thicker epidermal region (63 m increase in penetration depth).
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Figure 7. (A) MALDI-MSI distribution
of sodiated sphingomyelin (SM 34:1
[M+Na]+) at m/z 725.4 of LSEs 48 h post-
treatment across all treatment samples.
(B) Enlarged area MALDI-MSI data over-
lay of m/z 326.2 acetretin (green) on so-
diated sphingomyelin (SM 34:1 [M+Na]+)
at m/z 725.4 of LSEs 48 h posttreatment.
Apparent acetretin depth of penetration is
557 m, i.e. it has penetrated to within the
dermal region.
in the epidermal region in both psoriatic and nonpsoriatic
skin models whereas 48 h posttreatment it had penetrated
into the dermis.
We intend to utilize sphingomyelins (or different lipid,
peptide, or protein species) in combination with matrix sub-
limation to obtain high-resolution images of the epidermal
region of the LSE model in future studies.
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